Its full name is glucagon-like peptide-1, and its main job is to steady blood sugar after a meal
GLP-1 reduces appetite, slows gastric emptying, and improves insulin secretion
So Novo Nordisk went back to the drawing board and created semaglutide
The article suggests your gastrointestinal health history, your preference for daily versus weekly dosing, your past medication adherence patterns, and any contraindications
A structured approach is essential to manage any dosage adjustment and potential side effects
Their primary mechanisms include: Enhancing insulin secretion from pancreatic beta cells in response to elevated blood glucose Suppressing glucagon release , thereby reducing hepatic glucose production Slowing gastric emptying , which prolongs satiety and reduces appetite Acting on appetite centres in the brain , particularly the hypothalamus, to reduce food intake [17] [18] These combined effects lead to improved glycaemic control in people with type 2 diabetes and significant weight reduction in those using these medications for obesity management